Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.
about
Antipsychotic combinations for schizophreniaAntipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsPharmacotherapy of schizophrenic patients: preponderance of off-label drug useA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyEffectiveness of switching from antipsychotic polypharmacy to monotherapy.Cost of antipsychotic polypharmacy in the treatment of schizophrenia.Antipsychotic polypharmacy in a regional health service: a population-based study.Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Antipsychotic medication coprescribing in a large state hospital system.Implementing quality management in psychiatry: from theory to practice--shifting focus from process to outcome.Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.Factors related to prescription dosage in Japanese psychiatric hospitals.Antipsychotics dosage and antiparkinsonian prescriptions.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysisAntipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceBenefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient HospitalsAntipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Public-academic partnerships: a program to improve the quality of antipsychotic prescribing in a community mental health system.Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.Combination therapy or monotherapy for the depressed type of schizoaffective disorder.Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Explicit versus implicit review to explore combination antipsychotic prescribing.Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria.Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisPharmacotherapy for treatment-refractory schizophrenia.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Integration of Chinese medicine with Western medicine could lead to future medicine: molecular module medicine.Functioning in patients with schizophrenia: a systematic review of the literature using the International Classification of Functioning, Disability and Health (ICF) as a reference.Trends in antipsychotic prescribing in schizophrenia in Auckland.Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients.Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigmAntipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.
P2860
Q24234513-F184CF97-6530-4AE3-97EE-1958620CCAB6Q24811190-92463BE9-5C63-4ED7-B869-14F45C16D9DEQ28473574-62D2397A-1061-4573-BFD6-A63F7ACABD6AQ30485065-645BF6A7-122E-4FC9-8F44-B532EFB1933DQ30542484-8E53EE92-22C5-499E-9B90-46747BD69AB3Q33327172-1B88D46E-093C-4B17-ACF8-CD34F5851EF4Q34269517-E874A1D3-37AD-4D44-A928-5043ACC90355Q34491836-DC11AC9B-1762-41A0-8124-8E5F765D18F4Q34640811-8FA99A9E-ADB5-4D22-8340-2E916B5853FDQ35077883-6C36C8F8-6E55-4E8C-885D-96D56C97508EQ35217478-52802B5C-2B4F-4282-84FE-9E59EE495C47Q35568945-5D4BE767-4172-4AEF-85A7-E3096F10E026Q35826319-A9F1D192-A06C-4305-8A07-E24315D29677Q36023620-8AF4FF9C-3E05-430E-9C87-1BE65427F78DQ36054627-6FCF6E12-3C78-44C0-8444-529A288BF19CQ36057820-A3C16DBE-2444-47AA-BFD3-2A6C79669141Q36065092-6E1BBE99-380F-4578-BCF5-9836C7268EB2Q37029622-0E8E123F-3780-423D-A704-B8F965D24C1EQ37038719-79B567E9-6166-4B38-81A5-868A1F2DC2CFQ37042072-6A37E7FF-4FBA-4969-8BD5-B19EB41DF81EQ37116547-9023D098-7B39-48FE-84FA-144702157D71Q37137001-B2F65F51-8E69-4EC8-A545-0AB5DBA27EACQ37190577-7D36A9E6-3CBE-4AFC-99FB-746621A4289EQ37216848-323FF580-5F1C-461D-B58C-5163D8113FA9Q37224567-E37BE351-E88B-41CB-A739-6595464ED449Q37281587-7E32BD3C-0B79-4518-A296-5B3E0B9998FBQ37578712-D5BD5C1D-12C0-4A51-A844-A7B76A097FEFQ37582708-713A12E0-8194-4738-85D3-91B4BA4FD550Q37609168-8525E92C-44E3-47D6-A46E-9920C6725E35Q37831352-DA3E0151-4D6C-4908-9AAF-EACE4B1EDF3CQ37863093-18B45119-EB64-4DAD-A8D0-773F22546A5EQ38081872-2CC5B708-E3C7-4841-8CCD-84DC55077ACCQ38769838-AFA78F88-2FDE-4DDC-BFBF-F46923B2B723Q38802358-D81CD4E2-F76C-4669-A6D5-6568F2E8F84EQ39057150-57AEE936-4C2F-440D-9206-8BF2C0657673Q39756918-F3C768FC-A71A-430D-B639-E5459F2AAE24Q39874856-75676559-0715-46CD-81C3-6C1FDE646F25Q41064310-0A21390A-3A3A-4C75-8513-38B84EB0606BQ41890120-EC2F1399-4F3A-47BF-86D8-D4AFDD150159Q42707831-E61ED8F7-FD7E-4309-8EDF-06112C8DA92D
P2860
Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Recent trends in antipsychotic ...... or state mental health policy.
@en
Recent trends in antipsychotic ...... or state mental health policy.
@nl
type
label
Recent trends in antipsychotic ...... or state mental health policy.
@en
Recent trends in antipsychotic ...... or state mental health policy.
@nl
prefLabel
Recent trends in antipsychotic ...... or state mental health policy.
@en
Recent trends in antipsychotic ...... or state mental health policy.
@nl
P2093
P1476
Recent trends in antipsychotic ...... or state mental health policy.
@en
P2093
Robin E Clark
Stephen J Bartels
Thomas A Mellman
William J Peacock
P356
10.1093/OXFORDJOURNALS.SCHBUL.A006928
P407
P577
2002-01-01T00:00:00Z